Business
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Roivant Sciences","displaySize":"","headline":null,"caption":"Roivant Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/a57a72b6e3603bd6b96f169634edde44"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nw9vTdPw0x6jxsb4Xv0KMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a57a72b6e3603bd6b96f169634edde44","width":300,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"If the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Genevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products, ending all patent-infringement litigation against Moderna arising from its unauthorized use of the technology in its COVID-19 vaccines","length":364,"tagName":"p"}]},{"val":[{"type":"text","content":"Pfizer/BioNTech litigation is ongoing in the United States following a favorable Markman ruling issued in September 2025; Comirnaty sales represent ~2/3 of global COVID-mRNA vaccine sales to date","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Roivant’s board of directors has approved a $1 billion share repurchase program, inclusive of the $500 million authorization that was approved in June 2025","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Roivant will host an investor call to discuss these updates today, March 3, 2026, at 4:45 p.m. ET","length":97,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1322,"olType":false},{...